Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today provided an update on the continued advancement of its proprietary AI platform and robotics integration as it approaches initial commercial deployment. Following the successful integration of approximately 28 million scientific abstracts - representing the totality of scientific knowledge - into its PDAOAI platform, the Company has achieved another milestone to enable real-time application within its jointly developed robotics platform with TechForce Robotics.